XML 104 R71.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements and Investments - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Mar. 01, 2019
Feb. 14, 2019
Apr. 30, 2018
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Feb. 06, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Increase in fair value primarily attributable to change in forecast of future net sales         $ 29,100,000    
Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Milestone achievement period     5 years   12 months    
Contingent consideration         $ 42,700,000    
Spinal Kinetics [Member] | Other Current Liabilities [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Contingent consideration         14,700,000    
Spinal Kinetics [Member] | Other Long-term Liabilities [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Contingent consideration         $ 28,000,000.0    
Maximum [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments     $ 60,000,000.0        
US Food And Drug Administration [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments     15,000,000.0       $ 15,000,000.0
Payments obligation for contingent consideration   $ 15,000,000.0          
Revenue Milestone [Member] | Spinal Kinetics [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Future milestone payments     $ 45,000,000.0        
Bone Biologics Inc [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Warrants held for share purchases         13    
Weighted average exercise price of warrant         $ 10.00    
Warrants exercisable period         7 years    
Warrant expiration year         2020    
eNeura Inc [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Payments of restructured debt security       $ 4,000,000.0      
Adjusted carrying value of restructured debt       4,000,000.0      
Other-than-temporary impairment on restructured debt securities       6,500,000      
eNeura Inc [Member] | Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Unrealized gains on restructured debt securities       $ 5,200,000      
eNeura Inc [Member] | Amended and Restated Senior Secured Promissory Note [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Debt maturity date         Mar. 04, 2019    
Principal amount of the debt security         $ 15,000.0    
Accrued interest rate         8.00%    
Debt securities, maturity date description         Amended and Restated Senior Secured Promissory Note with eNeura (the “Restructured Debt Security”) to restructure the debt security, which extended the maturity date to the earlier of (i) March 4, 2022, (ii) the effective date of a change in control, or (iii) the effective date of an initial public offering by eNeura, and which also eliminated the conversion feature included within the original note.    
Warrant exercisable price per share $ 0.01            
Warrant contractual term 10 years            
Percentage of number of warrant issued equal to outstanding principal and accrued interest on debt security 10.00%            
Debt security subject to certain anti-dilution provision price per share $ 1.00            
Debt securities amortized cost basis           $ 9,000,000.0  
Equity Warrants [Member] | Bone Biologics Inc [Member]              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Warrants fair value Reduced           0  
Impairment charges on investment           $ 4,400,000